title: An assessment by the Statin Cognitive Safety Task Force: 2014 update.
abstract: The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.
authors.affiliation: Schlegel-UW Research Institute for Ageing; School of Public Health and Health Systems; School of Pharmacy, University of Waterloo, 10 Victoria Street S, Room 7004, Kitchener, Ontario N2G 1C5, Canada; Michael G. DeGroote School of Medicine, Department of Family Medicine, McMaster University, University of Waterloo, Hamilton, ON, Canada. Electronic address: carlos.rojas-fernandez@uwaterloo.ca.
authors.forename: Carlos H
authors.initials: CH
authors.lastname: Rojas-Fernandez
authors.affiliation: Duke Stroke Center, Duke University and Durham VAMC, Durham, NC.
authors.forename: Larry B
authors.initials: LB
authors.lastname: Goldstein
authors.affiliation: Department of Neurology, Emory University, Atlanta, GA.
authors.forename: Allan I
authors.initials: AI
authors.lastname: Levey
authors.affiliation: Department of Preventive Cardiology, Hartford Hospital & University of Hartford, Hartford, CT.
authors.forename: Beth A
authors.initials: BA
authors.lastname: Taylor
authors.affiliation: Division of Cardiovascular Disease, Preventive Cardiology Section, University of Alabama at Birmingham, Birmingham, AL.
authors.forename: Vera
authors.initials: V
authors.lastname: Bittner
authors.lastname: The National Lipid Association's Safety Task Force
mesh_terms: D000544:Alzheimer Disease / Q000453:epidemiology / Q000209:etiology; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control*; D003072:Cognition Disorders / Q000209:etiology; D060825:Cognitive Dysfunction / Q000209:etiology; D004359:Drug Therapy, Combination / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016017:Odds Ratio
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Adverse drug effects; Cognition; Iatrogenesis; Memory; Statins